title: Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer.
abstract: OBJECTIVE
  To evaluate clinical efficacy of a dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung (NSCLC).
  
  
  METHODS
  Patients with locally advanced NSCLC were treated with conventional fractionated radiotherapy or three dimensional conformal radiotherapy (3 DCRT), concurrently with a dose escalating schedule of paclitaxel. All patients were divided into three groups, A with paclitaxel 30 mg/m2, B with paclitaxel 60 mg/m2 and C with paclitaxel 90 mg/m2. Paclitaxel was repeated every week for a total of 4 or 6 weeks.
  
  
  RESULTS
  Among 109 patients, response rates were 68.8%, 71.1% and 71.8% (p>0.05) for group A (n=32), B (n=38), and C (n=39) respectively. Accordingly, disease control rates were 81.3%, 81.6% and 82.1% (p>0.05). Progression-free survival time was 8.0 ± 5.0 months, 11.6 ± 6.1 months, and 14.8 ± 7.9 months (p<0.05), respectively. Overall survival time was 15. 4 ± 7.6 months, 18.2 ± 8.0 months, and 22.0 ± 7.6 months (p<0.05), one-year survival rates were 62.5%, 73.1% and 90.0% (p>0.05) and two-year survival rates were 31.3%, 38.5% and 50.0% (p<0.05) . Main side-effects were bone marrow suppression, radiation related esophagitis and gastrointestinal reaction.
  
  
  CONCLUSIONS
  In treating patients with NSCLC, concurrent chemoradiotherapy with paclitaxel improves early response compared with conventional fractionated radiotherapy or 3 DCRT. The survival rate was improved with the addition of paclitaxel, but there was an increase in adverse reactions when the dose of paclitaxel was increased.
authors.affiliation: Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University, Taizhou, China E-mail : huangxinen06@aliyun.com.
authors.forename: Lin
authors.initials: L
authors.lastname: Cui
authors.forename: Xing-Xiang
authors.initials: XX
authors.lastname: Liu
authors.forename: Yong
authors.initials: Y
authors.lastname: Jiang
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Liu
authors.forename: Xiang-Rong
authors.initials: XR
authors.lastname: Zhou
authors.forename: Xue-Jun
authors.initials: XJ
authors.lastname: He
authors.forename: Jue
authors.initials: J
authors.lastname: Chen
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D059248:Chemoradiotherapy; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D020266:Radiotherapy, Conformal; D015996:Survival Rate
chemical_list: D017239:Paclitaxel